公开(公告)号：US12194032B2

公开(公告)日：2025-01-14

申请号：US17658494

申请日：2022-04-08

Applicant: ChemoCentryx, Inc.

Inventor： Zhenhua Miao ,  Thomas Schall ,  Rajinder Singh

IPC: A61K31/444 ,  A61K31/137 ,  A61K31/28 ,  A61K31/403 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/519 ,  A61K31/7034 ,  A61K35/545 ,  A61K39/395 ,  A61P13/12

Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

公开(公告)号：US12012403B2

公开(公告)日：2024-06-18

申请号：US17820281

申请日：2022-08-17

Applicant: CHEMOCENTRYX, INC.

Inventor： Penglie Zhang ,  Daniel R. Marshall ,  Howard S. Roth ,  Aubrie Harland

IPC: C07D471/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/20 ,  C07D513/04

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/20 ,  C07D513/04

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

公开(公告)号：US11945805B2

公开(公告)日：2024-04-02

申请号：US17243872

申请日：2021-04-29

Applicant: CHEMOCENTRYX, INC.

Inventor： Xi Chen ,  Dean R. Dragoli ,  Junfa Fan ,  Jaroslaw Kalisiak ,  Manmohan Reddy Leleti ,  Viengkham Malathong ,  Jeffrey McMahon ,  Hiroko Tanaka ,  Ju Yang ,  Chao Yu ,  Penglie Zhang ,  Venkat Mali

IPC: C07D405/12 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/4439 ,  A61K45/06 ,  A61P11/00 ,  A61P17/06 ,  A61P35/00 ,  A61P37/00 ,  C07B59/00 ,  C07D405/14 ,  C07D413/12

CPC classification number: C07D405/12 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/4439 ,  A61K45/06 ,  A61P11/00 ,  A61P17/06 ,  A61P35/00 ,  A61P37/00 ,  C07B59/002 ,  C07D405/14 ,  C07D413/12 ,  C07B2200/05 ,  A61K31/4035 ,  A61K2300/00 ,  A61K31/422 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00

Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:

公开(公告)号：US20230339851A1

公开(公告)日：2023-10-26

申请号：US18186265

申请日：2023-03-20

Applicant: CHEMOCENTRYX, INC.

Inventor： Hiufung CHU ,  Pingchen FAN ,  Yandong LI ,  Viengkham MALATHONG ,  Jay POWERS ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC: C07D231/14 ,  C07D261/18 ,  C07D317/60 ,  C07D237/24 ,  C07D309/10 ,  C07D275/03 ,  C07D319/12 ,  C07D307/24 ,  C07D207/16 ,  C07D309/06 ,  C07D493/08 ,  C07D295/195 ,  C07D239/28 ,  C07D307/16 ,  C07D265/30 ,  C07D309/28 ,  C07D309/08 ,  C07D211/60 ,  C07D207/22 ,  C07D233/90 ,  C07D317/66 ,  C07D211/62 ,  C07D335/02 ,  C07C311/44 ,  C07D307/68 ,  C07D213/81 ,  C07D471/08

CPC classification number: C07C311/44 ,  C07D207/16 ,  C07D207/22 ,  C07D211/60 ,  C07D211/62 ,  C07D213/81 ,  C07D231/14 ,  C07D233/90 ,  C07D237/24 ,  C07D239/28 ,  C07D261/18 ,  C07D265/30 ,  C07D275/03 ,  C07D295/195 ,  C07D307/16 ,  C07D307/24 ,  C07D307/68 ,  C07D309/06 ,  C07D309/08 ,  C07D309/10 ,  C07D309/28 ,  C07D317/60 ,  C07D317/66 ,  C07D319/12 ,  C07D335/02 ,  C07D471/08 ,  C07D493/08 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/18 ,  C07C2602/42

Abstract: Provided are sulfonamide compounds having formula (I):





or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

公开(公告)号：US11773091B2

公开(公告)日：2023-10-03

申请号：US17735283

申请日：2022-05-03

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Rebecca M. Lui ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Sreenivas Punna ,  Rajinder Singh ,  Hiroko Tanaka ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D471/04 ,  A61P37/02 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61P37/02 ,  C07D519/00

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I)




or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US11713307B2

公开(公告)日：2023-08-01

申请号：US17071077

申请日：2020-10-15

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Rebecca M. Lui ,  Darren J. McMurtrie ,  Ryan J. Scamp ,  Ju Yang ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D487/10

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/14 ,  C07D487/10

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I)




including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20230125684A1

公开(公告)日：2023-04-27

申请号：US17820281

申请日：2022-08-17

Applicant: CHEMOCENTRYX, INC.

Inventor： Penglie ZHANG ,  Daniel R. MARSHALL ,  Howard S. ROTH ,  Aubrie HARLAND

IPC: C07D471/04 ,  C07D471/10 ,  C07D401/14 ,  C07D487/04 ,  C07D413/14 ,  C07D405/14 ,  C07D491/107 ,  C07D513/04 ,  C07D417/14 ,  C07D491/20

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

公开(公告)号：US20230023075A1

公开(公告)日：2023-01-26

申请号：US17694829

申请日：2022-03-15

Applicant: CHEMOCENTRYX, INC.

Inventor： James J. CAMPBELL ,  Zhenhua MIAO ,  Thomas J. SCHALL ,  Israel CHARO ,  Shijie LI ,  Christine Marie JANSON ,  Rajinder SINGH ,  Karen EBSWORTH

IPC: A61K31/536 ,  A61P35/00 ,  A61K31/165 ,  A61K31/357 ,  A61K45/06

Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.

公开(公告)号：US11485708B2

公开(公告)日：2022-11-01

申请号：US16905979

申请日：2020-06-19

Applicant: CHEMOCENTRYX, INC.

Inventor： Viengkham Malathong ,  Pingchen Fan ,  Christopher Lange ,  Venkat Reddy Mali ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: C07D217/04 ,  A61K45/06 ,  C07D401/12 ,  A61K31/4725 ,  C07C217/58 ,  A61K31/137 ,  C07D211/58 ,  A61K31/4468 ,  A61K31/4545 ,  C07C229/16 ,  A61K31/197 ,  C07D207/06 ,  A61K31/40 ,  C07D319/18 ,  A61K31/357 ,  C07D213/64 ,  A61K31/4402 ,  C07D215/227 ,  A61K31/4704 ,  C07C309/14 ,  A61K31/185 ,  A61K31/472

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R5, R6, R7, R8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20220296601A1

公开(公告)日：2022-09-22

申请号：US17805280

申请日：2022-06-03

Applicant: CHEMOCENTRYX, INC.

Inventor： Zhenhua MIAO ,  Thomas J. Schall ,  Rajinder Singh

IPC: A61K31/519 ,  A61K31/41 ,  A61P13/12 ,  A61K31/437 ,  A61K31/422

Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.